United Statesfoundationmedicine.com
Foundation Medicine, Inc. is a precision medicine company that develops genomic profiling assays based on next-generation sequencing for oncology applications. Headquartered in Boston, Massachusetts, with additional laboratories in North Carolina and Germany, the company provides comprehensive genomic profiling tests to identify molecular alterations in solid tumors, hematologic malignancies, and other cancers. Founded in 2010, it has operated as a wholly owned subsidiary of Roche since completing its acquisition in 2018. Foundation Medicine focuses on companion diagnostics and supports treatment selection, clinical trial matching, and biopharmaceutical research in cancer care.
Also known as FMI.
None yet. When a new project in the record names Foundation Medicine as owner, partner or investor, it shows here.
Approval allows FoundationOne CDx to detect BRAF V600 alterations and BRAF fusion genes to guide tovorafenib treatment in glioma and expands companion indications to nine cancer types.
New single-molecule platform uses SBX chemistry and reusable CMOS nanopore sensors to deliver same-day whole‑genome sequencing, open-source analysis and flexible workflows.
First FDA-cleared IHC companion diagnostic to detect PTEN protein loss and select patients for capivasertib (TRUQAP) plus abiraterone therapy.
